4//SEC Filing
BENNETT C FRANK 4
Accession 0000874015-25-000075
CIK 0000874015other
Filed
Feb 2, 7:00 PM ET
Accepted
Feb 3, 7:26 PM ET
Size
7.2 KB
Accession
0000874015-25-000075
Insider Transaction Report
Form 4
BENNETT C FRANK
EVP, Chief Scientific Officer
Transactions
- Sale
Common Stock
2025-01-31$32.46/sh−1,327$43,079→ 93,146 total - Award
Common Stock
2025-01-30+3,607→ 94,473 total
Footnotes (2)
- [F1]Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs") for the final performance period of the grant to the reporting person reported on January 19, 2022. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 150% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 150% based on actual achievement of the goal.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.21 to $32.86 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
Documents
Issuer
IONIS PHARMACEUTICALS INC
CIK 0000874015
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001073387
Filing Metadata
- Form type
- 4
- Filed
- Feb 2, 7:00 PM ET
- Accepted
- Feb 3, 7:26 PM ET
- Size
- 7.2 KB